Skin Cancer & Melanoma

Latest News

Patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody can now receive lifileucel after accelerated approval from the FDA.
Accelerated Approval Given to Lifileucel in Metastatic Melanoma

February 16th 2024

Patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody can now receive lifileucel after accelerated approval from the FDA.

The DermaSensor device demonstrates a high rate of sensitivity in the detection of more than 200 types of skin cancers in a clinical study.
FDA Clears Non-Invasive AI Device for Skin Cancer Detection

January 18th 2024

Results from a long-term analysis of the phase 3 IMCgp100-202 trial indicate that tebentafusp results in better disease control and long-lasting responses in those with HLA-A*02:01–positive, previously untreated metastatic uveal melanoma.
Tebentafusp Continues to Demonstrate Benefit in Metastatic Uveal Melanoma

January 4th 2024

Individualized Neoantigen Therapy/Pembrolizumab Improves RFS in Melanoma
Individualized Neoantigen Therapy/Pembrolizumab Improves RFS in Melanoma

December 18th 2023

Treatment with mRNA-4157 plus pembrolizumab yields benefits in resected melanoma subgroups in the phase 2 KEYNOTE-942 trial, including those with BRAF-mutated tumors.
mRNA Vaccine/Pembrolizumab Significantly Improves RFS in Resected Melanoma

October 23rd 2023

Video Series
Video Interviews
Podcasts
OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma
On this episode of CancerNetwork’s podcast, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY.

More News